Urinary tract infections. 2. Therapeutic approach.
Acute urethral syndrome is effectively treated with a standard course of an appropriate oral antibiotic. Cystitis can be treated similarly but, because it is regarded as benign in normal hosts, may be better treated symptomatically. Acute pyelonephritis requires a parenteral antibiotic because of its frequent association with bacteremia. In chronic pyelonephritis, an oral antibiotic is chosen for long-term use on the basis of its ability to penetrate damaged renal tissue. When urinary tract infection recurs, reinfection must be differentiated from relapse. Reinfection usually requires long-term antimicrobial therapy, but relapse often has a potentially reversible underlying cause and merits extensive diagnostic workup. Chronic prostatitis constitutes a greater therapeutic problem than acute prostatitis because of difficulty with antibiotic penetration.
D000038:Abscess / Q000188:drug therapy; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000188:drug therapy; D003556:Cystitis / Q000188:drug therapy; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy; D008297:Male; D011472:Prostatitis / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D014522:Urethral Diseases / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary